ArticleNucleic acids research2026
PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data.bioRxiv : the preprint server for biology · 2026Article
- The 2026 Nucleic Acids Research database issue and the online molecular biology database collection.Nucleic acids research · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Gene expression can be used to define prognostic and predictive biomarkers across cancers and treatment modalities. PRECOG (https://precog.stanford.edu) is a compendium of datasets with gene expression and clinical outcomes that facilitates visualization of associations between genomic profiles and patient survival. Here, we augment the existing PRECOG with over 10 000 new patients in previously poorly represented adult cancer types, as well as adding annotated pediatric and immunotherapy treated cohorts. Pediatric PRECOG comprises over 3000 patients across 12 cancers; while the checkpoint inhibitor (ICI) PRECOG contains over 4000 patients across 20 cancer subtypes from 80 distinct datasets across 51 studies. Together this represents a doubling in the size of the PRECOG database. We compute and visualize associations of gene expression with survival outcomes using Cox regression for time-to-event, or logistic regression for responder versus nonresponder, across all datasets. We also estimate cell type fractions in samples via computational deconvolution using CIBERSORTx, to identify survival associations at the level of cell types. All expression data, clinical annotations, and gene and cell type survival z-scores and meta-z scores for adult, pediatric, and ICI PRECOG, are available for interactive analysis and download, along with Kaplan-Meier and boxplot visualizations. This updated resource will provide new insights into biomarkers for specific therapies, populations, and cancer types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.